Glioblastoma Clinical Trials in Boston, MA

View the best 10 glioblastoma medical studies in Boston, Massachusetts. Access promising new therapies by applying to a Boston-based Glioblastoma clinical trial.

Trials in Boston, Massachusetts

Here are the top 10 medical studies for glioblastoma in Boston, Massachusetts

Michael Bask Gill, B Sc

Last Reviewed: December 1st, 2024

Berubicin +1 More

Anthracenedione

Recruiting1 awardPhase 2

This trial will compare the effect of two cancer drugs, berubicin and lomustine, on overall survival in patients with glioblastoma multiforme (GBM) who have failed standard first line therapy. A futility analysis will be performed after approximately 30-50% of planned patients have completed the primary endpoint at 6 months.

RO7428731

Monoclonal Antibodies

Recruiting1 awardPhase 1

This trial tests a new drug, RO7428731, for safety and effectiveness in patients with a specific type of brain cancer (glioblastoma) that has a particular mutation. The drug works by targeting and binding to the mutated cancer cells to stop their growth. This mutation is common in glioblastoma and makes the cancer grow faster and resist standard treatments.

Temozolomide +2 More

Alkylating Agent

Recruiting1 awardPhase 2

This trial is testing a combination of three drugs to treat brain tumors that have come back after previous treatments. The drugs help the immune system attack the tumor, stop the tumor cells from repairing themselves, and prevent them from growing. About 66-78 people will participate in this study.

Personalized NeoAntigen Vaccine +1 More

Cancer Vaccine

Recruiting1 awardPhase 1

This trial is studying a new type of vaccine as a possible treatment for patients with glioblastoma. It is evaluating the safety of the vaccine and finding the right dose to use.

BDTX-1535

Small Molecule Inhibitor

Recruiting1 awardPhase 1 & 2

This trial is testing a new drug for people with glioblastoma or non-small cell lung cancer who have disease progression following standard of care.

BGB-290 +1 More

PARP Inhibitor

Recruiting1 awardPhase 1

This trial studies the safety and best dose of BGB-290 and temozolomide in treating young people with a specific type of brain tumor. BGB-290 blocks enzymes needed for tumor growth, while temozolomide kills or stops cancer cells from growing. The goal is to find out if this combination works better for these patients.

AB154 +1 More

Monoclonal Antibodies

Recruiting0 awardsPhase < 1

This trial is testing a new combination of drugs to treat glioblastoma, a type of brain cancer. The trial is divided into two groups, with the first group receiving the new combination of drugs to test for safety and the second group receiving the new combination of drugs as well as surgery.

Atezolizumab +1 More

Monoclonal Antibodies

Recruiting1 awardPhase 2

This trial tests a combination of tocilizumab, atezolizumab, and precise radiation therapy in patients with recurrent glioblastoma. Tocilizumab reduces inflammation, atezolizumab boosts the immune system, and the radiation targets the tumor. The goal is to make the tumor more responsive to treatment and improve patient outcomes.

GammaTile radiation therapy implantation +3 More

Brachytherapy

Recruiting3 awardsPhase 4

This trial tests if adding GammaTile radiation therapy to standard treatment can improve outcomes for patients with newly diagnosed GBM. GammaTile delivers quick, direct radiation to the tumor, which may help control the tumor better and improve survival rates.

Temozolomide +1 More

Alkylating agents

Recruiting1 awardPhase 2

This trial is testing a new drug called OKN-007 combined with a chemotherapy drug, temozolomide, in patients whose brain cancer has returned after standard treatments. OKN-007 may help reduce tumor growth and make the chemotherapy more effective. Temozolomide is effective in treating malignant brain tumors.

Popular Filters

Trials With No Placebo

Anthracenedione

Berubicin for Glioblastoma

Recruiting1 awardPhase 2

Boston, Massachusetts

This trial will compare the effect of two cancer drugs, berubicin and lomustine, on overall survival in patients with glioblastoma multiforme (GBM) who have failed standard first line therapy. A futility analysis will be performed after approximately 30-50% of planned patients have completed the primary endpoint at 6 months.

Monoclonal Antibodies

Tocilizumab + Atezolizumab + Radiation Therapy for Glioblastoma

Recruiting1 awardPhase 2

Worcester, Massachusetts

This trial tests a combination of tocilizumab, atezolizumab, and precise radiation therapy in patients with recurrent glioblastoma. Tocilizumab reduces inflammation, atezolizumab boosts the immune system, and the radiation targets the tumor. The goal is to make the tumor more responsive to treatment and improve patient outcomes.

Device

Optune + Radiation & Chemotherapy for Brain Cancer

Recruiting1 award12 criteria

Boston, Massachusetts

This trial is testing a new treatment for brain cancer that combines Optune with radiation and chemotherapy. The goal is to see if this new combination is more effective and has fewer side effects than current treatments.

Clindamycin + Triamcinolone for Glioblastoma Skin Side Effects

Recruiting1 awardPhase 2

Boston, Massachusetts

This trial will test whether using clindamycin and triamcinolone topical lotions can prevent skin-related side effects for people being treated with Tumor Treating Fields for malignant glioma.

Checkpoint Inhibitor

Ipilimumab + Nivolumab + Radiation for Glioblastoma

Recruiting1 awardPhase 2 & 3

Hartford, Connecticut

This trial is testing whether adding immunotherapy to radiation therapy can help people with newly diagnosed glioblastoma that has an unmethylated MGMT.

Alkylating agents

OKN-007 + Temozolomide for Recurrent Brain Cancer

Recruiting1 awardPhase 2

Providence, Rhode Island

This trial is testing a new drug called OKN-007 combined with a chemotherapy drug, temozolomide, in patients whose brain cancer has returned after standard treatments. OKN-007 may help reduce tumor growth and make the chemotherapy more effective. Temozolomide is effective in treating malignant brain tumors.

View more glioblastoma clinical trials boston

See more medical studies focusing on glioblastoma boston

Frequently Asked Questions

Do I need insurance to participate in a trial?

Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).

Is there any support for travel costs?

Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.

Will I know what medication I am taking?

This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.

How long do clinical trials last?

Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.

Do you verify all the trials on your website?

All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.

How quickly will I hear back from a clinical trial?

Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.